Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment

G. Bianchetti, G. Graziani, D. Brancaccio, A. Morganti, G. Leonetti, M. Manfrin, R. Sega, R. Gomeni, C. Ponticelli, P. L. Morselli

Research output: Contribution to journalArticle

Abstract

Propranolol blood and plasma levels were measured after a single oral dose of 40mg in patients with chronic renal failure, in patients undergoing regular dialysis treatment, and in healthy volunteers. Peak levels were observed in all cases within 1.5 to 3 hours. However, peak blood and plasma concentrations of propranolol in the chronic renal failure group were 2- to 3-fold higher (161 ± 41ng/ml) than those observed in the dialysis patients (47 ± 9ng/ml) and in the healthy volunteers (26 ± 1ng/ml). The apparent plasma clearance was also significantly reduced in the patients with chronic renal failure. The data suggest a reduced hepatic extraction in chronic renal failure patients. A significant increase in the fraction of the dose available to the systemic circulation was also found, together with a modification of apparent plasma half-life and volume of distribution in regular dialysis patients during the dialysis day as compared with the after-dialysis day. No extraction of propranolol by the dialyzer was noticed. Marked fluctuations in propranolol blood concentrations were also observed in patients on regular dialysis following continuous propranolol treatment. The suppressive effect of propranolol on plasma renin activity did not fully correlate with the hypotensive effect of the drug. On the basis of the reported data, propranolol should be used with great caution and at low doses in chronic renal failure.

Original languageEnglish
Pages (from-to)373-384
Number of pages12
JournalClinical Pharmacokinetics
Volume1
Issue number5
DOIs
Publication statusPublished - 1976

Fingerprint

Propranolol
Dialysis
Pharmacokinetics
Chronic Kidney Failure
Therapeutics
Healthy Volunteers
Renin
Half-Life
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Bianchetti, G., Graziani, G., Brancaccio, D., Morganti, A., Leonetti, G., Manfrin, M., ... Morselli, P. L. (1976). Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment. Clinical Pharmacokinetics, 1(5), 373-384. https://doi.org/10.2165/00003088-197601050-00004

Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment. / Bianchetti, G.; Graziani, G.; Brancaccio, D.; Morganti, A.; Leonetti, G.; Manfrin, M.; Sega, R.; Gomeni, R.; Ponticelli, C.; Morselli, P. L.

In: Clinical Pharmacokinetics, Vol. 1, No. 5, 1976, p. 373-384.

Research output: Contribution to journalArticle

Bianchetti, G, Graziani, G, Brancaccio, D, Morganti, A, Leonetti, G, Manfrin, M, Sega, R, Gomeni, R, Ponticelli, C & Morselli, PL 1976, 'Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment', Clinical Pharmacokinetics, vol. 1, no. 5, pp. 373-384. https://doi.org/10.2165/00003088-197601050-00004
Bianchetti, G. ; Graziani, G. ; Brancaccio, D. ; Morganti, A. ; Leonetti, G. ; Manfrin, M. ; Sega, R. ; Gomeni, R. ; Ponticelli, C. ; Morselli, P. L. / Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment. In: Clinical Pharmacokinetics. 1976 ; Vol. 1, No. 5. pp. 373-384.
@article{d8d1dc6937af4c019d144ea8a38ad873,
title = "Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment",
abstract = "Propranolol blood and plasma levels were measured after a single oral dose of 40mg in patients with chronic renal failure, in patients undergoing regular dialysis treatment, and in healthy volunteers. Peak levels were observed in all cases within 1.5 to 3 hours. However, peak blood and plasma concentrations of propranolol in the chronic renal failure group were 2- to 3-fold higher (161 ± 41ng/ml) than those observed in the dialysis patients (47 ± 9ng/ml) and in the healthy volunteers (26 ± 1ng/ml). The apparent plasma clearance was also significantly reduced in the patients with chronic renal failure. The data suggest a reduced hepatic extraction in chronic renal failure patients. A significant increase in the fraction of the dose available to the systemic circulation was also found, together with a modification of apparent plasma half-life and volume of distribution in regular dialysis patients during the dialysis day as compared with the after-dialysis day. No extraction of propranolol by the dialyzer was noticed. Marked fluctuations in propranolol blood concentrations were also observed in patients on regular dialysis following continuous propranolol treatment. The suppressive effect of propranolol on plasma renin activity did not fully correlate with the hypotensive effect of the drug. On the basis of the reported data, propranolol should be used with great caution and at low doses in chronic renal failure.",
author = "G. Bianchetti and G. Graziani and D. Brancaccio and A. Morganti and G. Leonetti and M. Manfrin and R. Sega and R. Gomeni and C. Ponticelli and Morselli, {P. L.}",
year = "1976",
doi = "10.2165/00003088-197601050-00004",
language = "English",
volume = "1",
pages = "373--384",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment

AU - Bianchetti, G.

AU - Graziani, G.

AU - Brancaccio, D.

AU - Morganti, A.

AU - Leonetti, G.

AU - Manfrin, M.

AU - Sega, R.

AU - Gomeni, R.

AU - Ponticelli, C.

AU - Morselli, P. L.

PY - 1976

Y1 - 1976

N2 - Propranolol blood and plasma levels were measured after a single oral dose of 40mg in patients with chronic renal failure, in patients undergoing regular dialysis treatment, and in healthy volunteers. Peak levels were observed in all cases within 1.5 to 3 hours. However, peak blood and plasma concentrations of propranolol in the chronic renal failure group were 2- to 3-fold higher (161 ± 41ng/ml) than those observed in the dialysis patients (47 ± 9ng/ml) and in the healthy volunteers (26 ± 1ng/ml). The apparent plasma clearance was also significantly reduced in the patients with chronic renal failure. The data suggest a reduced hepatic extraction in chronic renal failure patients. A significant increase in the fraction of the dose available to the systemic circulation was also found, together with a modification of apparent plasma half-life and volume of distribution in regular dialysis patients during the dialysis day as compared with the after-dialysis day. No extraction of propranolol by the dialyzer was noticed. Marked fluctuations in propranolol blood concentrations were also observed in patients on regular dialysis following continuous propranolol treatment. The suppressive effect of propranolol on plasma renin activity did not fully correlate with the hypotensive effect of the drug. On the basis of the reported data, propranolol should be used with great caution and at low doses in chronic renal failure.

AB - Propranolol blood and plasma levels were measured after a single oral dose of 40mg in patients with chronic renal failure, in patients undergoing regular dialysis treatment, and in healthy volunteers. Peak levels were observed in all cases within 1.5 to 3 hours. However, peak blood and plasma concentrations of propranolol in the chronic renal failure group were 2- to 3-fold higher (161 ± 41ng/ml) than those observed in the dialysis patients (47 ± 9ng/ml) and in the healthy volunteers (26 ± 1ng/ml). The apparent plasma clearance was also significantly reduced in the patients with chronic renal failure. The data suggest a reduced hepatic extraction in chronic renal failure patients. A significant increase in the fraction of the dose available to the systemic circulation was also found, together with a modification of apparent plasma half-life and volume of distribution in regular dialysis patients during the dialysis day as compared with the after-dialysis day. No extraction of propranolol by the dialyzer was noticed. Marked fluctuations in propranolol blood concentrations were also observed in patients on regular dialysis following continuous propranolol treatment. The suppressive effect of propranolol on plasma renin activity did not fully correlate with the hypotensive effect of the drug. On the basis of the reported data, propranolol should be used with great caution and at low doses in chronic renal failure.

UR - http://www.scopus.com/inward/record.url?scp=0017132594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017132594&partnerID=8YFLogxK

U2 - 10.2165/00003088-197601050-00004

DO - 10.2165/00003088-197601050-00004

M3 - Article

C2 - 1017154

AN - SCOPUS:0017132594

VL - 1

SP - 373

EP - 384

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 5

ER -